THERAPY DOSSIER · th-6699da1e02a2

Formononetin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL242341 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: 7-hydroxy-4'-methoxyisoflavone; Biochanin b; Formononetin; Formononetol; Neochanin; NSC-93360
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28234915 ↗2017Reported benefit

Formononetin protects against acetaminophen-induced hepatotoxicity through enhanced NRF2 activity.

MouseChemical/toxinBALB/cMalen = 4-6 mice per group across four groups; 4 per group for Nrf2…Oral gavage (formononetin dissolved in 0.5% CMC-Na)50 mg/kg and 100 mg/kgPre-treatment, given daily for seven consecutive days before the acetaminophen…

Model: Acetaminophen-induced acute liver injury by a single intraperitoneal dose of 300 mg/kg acetaminophen dissolved in PBS pH 7.4

Formononetin at 100 mg/kg reduced hepatic malondialdehyde from 1.97 plus or minus 0.27 to 0.55 plus or minus 0.14 nmol/mg protein, ALT from 955.80 plus or minus 209.40 to 46.90 plus or minus 20.40 IU/L and AST from 1533.80 plus or minus 244.80 to 56.70 plus or minus 28.80 IU/L (all p < 0.001), rais…

Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

Loading the evidence…